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Abstract 
Objectives: To examine trends and disparities in the quality of diabetes care among US adults with diabetes. Methods: Individuals aged 
20 years or older with diabetes from NHANES (1999-2016) were included in the study. Quality indicators for diabetes care included 
Hemoglobin A1c (HbA1c) < 8%, Blood Pressure (BP) < 130/80 mm Hg, Low-Density Lipoprotein (LDL-C) < 100 mg/dL, triglycerides < 150 
mg/dL, receiving eye and foot examinations in the past year, and meeting with a diabetes educator in the past year. Results: A total of 
7,521 adults with diabetes were identified. During the 18-year study period, significant improvements in diabetes care were observed 
in the overall study sample. Adjusted regression analyses showed that compared with their White counterparts, Blacks were more likely 
to have received eye (OR=1.37; P=0.01) and foot (OR=1.42;P=0.01) examinations and met a diabetes educator (OR=1.40;P<0.01) over 
the past year. However, Blacks were significantly less likely to achieve treatment goals for HbA1c (OR=0.77, P=0.02), BP (OR=0.75, 
P<0.01), LDL-C (OR=0.68, P<0.01). Hispanics in general had suboptimal healthcare utilization for diabetes but the Hispanic-white 
disparities in diabetes care outcomes were attenuated after controlling for patient sociodemographic, clinical and utilization 
characteristics. Overall, suboptimal quality of diabetes care were particularly prominent among adults without health insurance and 
those with lower educational attainment. Conclusions: In the United States, despite persistent efforts, racial disparities in quality of 
diabetes care still persist. Lack of health insurance and lower socioeconomic status are among the strongest predictors of poor quality 
of diabetes care. These findings provide valuable information in developing policies and practices to promote racial equity in diabetes 
care.   
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Introduction 
Diabetes mellitus (diabetes) is one of the most prevalent 
chronic disorders in the United States (US). Based on National 
Diabetes Statistics Report of 2017, 30.2 million (12.2%) US 
adults have diabetes (1). It is a leading risk factor for 
atherosclerotic cardiovascular disease (ASCVD), heart failure, 
and microvascular complications. At present, diabetes is the 
seventh leading cause of death in the US and the rates of the 
disease have been steadily increasing over the past two 
decades (2, 3). Over time, uncontrolled diabetes can lead to 
kidney failure and diseases of the lower limbs and feet. Given 
that there is no cure for diabetes, prevention and disease 
management are the two key approaches to lessening the 
morbidity and mortality associated with diabetes.  
 
The control of risk factors for diabetes care has improved but 
considerable gaps prevail between guideline recommendations 
and quality of care in the U.S. (2, 3), especially among certain 
patient groups.  Clinical guidelines have been established for 
diabetes management and control of its risk factors to increase 
life expectancy (4). More specifically the guidelines emphasize  
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on the management of atherosclerotic disease to encompass 
the prophylactic use of aspirin, control of hypertension and 
hyperlipidemia, and smoking cessation.  Furthermore, the 
guidelines also recommend the prevention and treatment of 
macrovascular diseases. The latter include early detection and 
treatment for retinopathy and nephropathy, routine food care, 
lifestyle modifications, treatment intensification and patient 
education for self-management of diabetes (4). To obtain a 
better understanding of the trends in quality of diabetes care 
and potential disparities among patient subgroups, we 
systematically analyzed the latest available data from a 
nationally representative sample. 
 
Methods 
Study participants 
The National Health and Nutrition Examination Survey 
(NHANES) is conducted by the Centers for Disease Control and 
Prevention’s (CDC) National Center for Health Statistics (NCHS). 
Survey respondents were selected using a complex, stratified, 
multistage probability sampling design of the US 
noninstitutionalized civilian population (5). Since 1999, 
NHANES has been implemented as a continuous, cross-
sectional annual survey, with data publicly released in 2-year 
cycles. Surveys data are gathered through detailed in-person 
home interviews, followed by standardized physical 
examinations conducted in mobile examination centers, and 
laboratory tests using blood and urine specimens provided by 
participants during the physical examination. The overall 
participant response rate ranged from 61.3% to 84% for 
interviews, and 68.5% to 80% for examinations at mobile 
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examination centers (MECs) for each survey cycle from 1999 to 
2016.  The surveys were reviewed and approved by the NCHS 
Institutional Review Board (IRB) and informed consent was 
obtained from participants.  
 
Definition of diabetes 
Diabetes was defined if one or more of the following conditions 
were met: 1) a positive response to one or more of the 
following questions: “Other than during pregnancy, have you 
ever been told by a doctor that you have diabetes?”, “Are you 
now taking insulin?”, “Are you now taking diabetic pills to lower 
your blood sugar?”; 2) diabetes medication(s) reported and 
brought to examination by the interviewee; 3) fasting plasma 
glucose ≥ 7mmol/L; 4) glycosylated hemoglobin (HbA1c) ≥ 6.5% 
(6,7). All patients with diabetes aged 20 years and older at the 
time of the survey were included in this analysis.  
 
Predictor variables 
Race and ethnicity were self-reported and were grouped into 
four categories: whites, blacks, Hispanics, and others.  Health 
insurance status is determined by response to the question 
“Are you covered by health insurance or some other kind of 
healthcare plan?” Participants with an affirmative answer were 
categorized into “insured” and negative answer “uninsured”.  
 
Socioeconomic status (SES) was measured using self-reported 
education and family income of the participant. Education 
categories included were “< high school,”  “high school 
graduate,” “some college”, and “college graduate or above”.  
Poverty levels were computed from a ratio of family income to 
poverty threshold: Poverty Income Ratio (PIR). Values were 
grouped as “<100% PIR,” “100-299% PIR,” “300-499% PIR” and 
“≥ 500% PIR.” 
 
Outcome variables 
Glycated hemoglobin (HbA1c) is the primary outcome measure 
used for monitoring the average blood glucose concentration in 
individuals with diabetes. The existence of hypertension as a 
co-morbidity of diabetes is damaging because of the negative 
health impact the  two conditions have on  cardiovascular 
events, neuropathy, retinopathy, and nephropathy (8). Diabetic 
dyslipidemia, characterized by high plasma triglyceride 
concentration, high Low-Density Lipoprotein Cholesterol (LDL-
C) and low High-Density Lipoprotein (HDL) concentration is 
another major risk factor for cardiovascular diseases in 
diabetes. Considering the risk factors for diabetes, we assessed 
the quality of care for diabetes and included the following 
quality indicators: HbA1c < 8%, Blood Pressure (BP) < 130/80 
mmHg, Low-Density Lipoprotein (LDL-C) < 100 mg/dL, 
triglycerides < 150 mg/dL, receipt of eye in the past year, foot 
examinations in the past year, and meeting with a diabetes 
educator in the past year. 
   HbA1c was examined in this analysis as both continuous and 
binary variables. A reasonable goal of < 7% is defined by 
American Diabetes Association (ADA) for nonpregnant adults. 
However, ADA recommends a less stringent goal of < 8% based 
on variation in life expectancies, number of co-morbid 
conditions, and duration of diabetes (9). Glycemic control of < 
8% was added in response to previous studies that reported 
older adults with diabetes are less likely to benefit from 
stringent HbA1c management (10).  For this study, HbA1c of > 
8% was considered suitable for uncontrolled diabetes taking 
into account this variability. 
Mean systolic and diastolic blood pressure (BP) were 
determined per NHANES reporting guidelines. Up to 3 BP 
readings were obtained and used to calculate a mean systolic 
BP and a mean diastolic BP for each individual. A detailed 
description of the procedures for BP measurement in NHANES 
has been published elsewhere (11). Hypertension control was 
defined as SBP < 130 mm Hg and DBP < 80 mm Hg (12). 
The 2013 American College of Cardiology (ACC)/American Heart 
Association  (AHA) guidelines define low-density lipoprotein 
cholesterol (LDL-C) goal of < 100 mg/dL and a goal of < 150 
mg/dL for triglycerides recommended for patients with 
diabetes (13). Total cholesterol and HDL-C were measured 
directly through NHANES data collection. LDL-C levels were 
estimated for people who fasted properly (for ≥ 8 hours and < 
24 hours) using the following equation [LDL cholesterol = (total 
cholesterol) – (HDL cholesterol) – (triglycerides/5)]. Estimates 
for the prevalence of achieving valid LDL-C was based on the 
fasting sample only.  
Receipt of eye examination was evaluated based on 
participants’ response to a question “When was the last time 
you had an eye exam in which the pupils were dilated?”. If 
participants reported receiving an eye exam within the past 
year then eye exam was coded as “yes”. Respondents were 
considered to have had foot examination if they responded 
once or more to the question “During the past 12 months, 
about how many times has a doctor or other health 
professional checked feet for any sores or irritations?”. Meeting 
with a diabetes educator in the past year was based on the 
question: “When was the last time you saw a diabetes nurse 
educator, dietician, or nutritionist?” and was coded as “Yes” for 
the response was “less than one year” and “no” for “more than 
one year”.  
 
Covariates 
Respondents’ age, gender, marital status, smoking status, Body 
Mass Index (BMI), utilization of diabetes medications, statin use 
and history of physician-diagnosed cardiovascular disease 
(CVD) (including stroke, congestive heart failure, angina 
pectoris, myocardial infarction, or coronary artery disease) 
were obtained through a questionnaire. 
 
Hypertension was defined if one or more of the following 
conditions were met: 1) systolic BP ≥ 140 mm Hg; 2) diastolic BP 
≥ 90 mm Hg; and an affirmative response to “Are you currently 
taking medication to lower your blood pressure?” (12). 
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Chronic kidney disease (CKD) was defined as either an 
estimated glomerular filtration rate (eGFR) <60 mL-1min-11.73 
m2 or a urinary albumin concentration of  > 200 mg g-1 urinary 
creatinine, where eGFR was estimated using the Chronic Kidney 
Disease Epidemiological Collaboration equation (14). Serum 
creatinine levels from  1999-2000 and 2005-2006 were 
calibrated as per NHANES documentation (15). Albuminuria 
was defined as Albumin-to-Creatinine ratio > 30 mg g-1 (16). 
 
Statistical Methods 
Descriptive statistics were used to assess the differences in 
sociodemographic and clinical characteristics. Appropriate 
sampling weights were used to account for differential 
probabilities of selection and the complex multistage sampling 
design. Additional sample weights were used to account for 
non-response and missing data. Taylor linearization was used 
for variance estimation and domain analysis was used for 
subpopulation analyses because selection of subpopulations 
may be unrelated to sample design. Trends in the performance 
of quality indicators for diabetes care were assessed with  
SAS survey procedures (PROC SURVEYREG and PROC 
SURVEYLOGISITC). To examine the factors affecting the quality 
of diabetes care, adjusted logistic regression models were 
constructed with quality indicators as the dependent variable 
and odds ratios and 95% confidence intervals were estimated. 
All the statistical analyses were conducted using SAS (version 
9.4.3, SAS Institute Inc., Cary, NC, USA) with a level of 
significance set at 0.05.   
Results  
A total of 7,521 adults with diabetes were identified and 
included in the analysis. A significant rise in the proportion of 
adults with some college education (25.8% to 32.4%; Ptrend < 
0.001) and individuals who were college graduates (14.6% to 
21.3%; Ptrend < 0.001) was observed during the study period 
(Supplemental table 1). During the same time, the percentage 
of whites decreased from 63.8% to 58.2% (Ptrend =0.01). 
  
Improvements were observed in meeting the HbA1c goals in 
many patient subgroups, such as individuals with less than high 
school education (66.8% to 71.2%, Ptrend < 0.001), those with a 
PIR of <100% (67.8% to 71.5%,Ptrend=0.02), insured participants 
(from 75.4% to 82.5%;Ptrend<0.001) and adults taking oral 
diabetes medications (72.6% to 84%;Ptrend<0.001) (Table 1). 
Significant increase in achieving BP goals were noted for  
whites (44.5% to 53.8%; Ptrend=0.01), blacks (43.8% to 
53.3%;Ptrend=0.03), as well as for adults with insurance (47.0% 
to 57.4%;Ptrend < 0.001) (Table 2). 
 
The overall rates of achieving LDL-C and triglycerides goals were 
46.6% (Table 3) and 53.0% (Table 4), respectively. The rate of 
meeting LDL-C goal improved significantly for whites (34.6% to 
56.9%; Ptrend <0.001), blacks (27.9% to 45.5%; Ptrend=0.02), 
insured (41.7% to 54.0% ;Ptrend=0.02), and statin users (45.7% to 
72.1%;Ptrend <0.01). (Table 3). Significant improvement in 
triglyceride control was observed among individuals with PIR 
<100% (32.0% to 51.0%; Ptrend=0.01), insured individuals (47.0% 
to 60.8% Ptrend=0.02), statin users (49.5% to 64.2%; Ptrend=0.02) 
and for those with certain comorbidities: hypertension (45.4% 
to 59.5%; Ptrend=0.03), chronic kidney disease (46.4% to 64.7%; 
Ptrend <0.001), and cardiovascular disease (40.1% to  
55.9%;Ptrend=0.02) (Table 4).  
 
Table 5 presents adjusted results evaluating the impact of 
sociodemographic and clinical characteristics on quality of 
diabetes care. Older (≥ 60 years) individuals with diabetes were 
74.7% more likely to have controlled HbA1c levels and 36% less 
likely to meet BP goal when compared with their younger con. 
Compared to patients with less than high school education, 
college graduates were 41.5% more likely to achieve HbA1c 
goal (P=0.03). The likelihood of achieving HbA1c and BP goals 
was found to be lower among blacks, Hispanics and individuals 
without insurance. Patients taking oral diabetes medications 
were 2.4 times more likely to have achieved HbA1c goal 
compared to untreated (P<0.001).  
 
Compared with their younger counterparts, individuals aged 60 
year or over were 23.6% less likely to achieve triglycerides goal 
(P=0.02) but were 26.5% more likely to achieve LDL-C goal. 
Although blacks were less likely to meet LDL-C goal than whites, 
the likelihood of achieving triglyceride goal was found to be 3.6 
times higher among blacks. The likelihood of meeting guideline 
recommended triglyceride goal also decreased with elevated 
BMI. The likelihoods of receiving eye examination, foot 
examination and meeting with a diabetes educator were 
substantially higher among older adults. Blacks were 41.9% 
more likely (P=0.01) and Hispanics 17.3% less likely (P=0.03) 
than whites to have foot examination over the past year.  
 
Discussion 
The current cross-sectional study was based on National Health 
and Nutrition Examination Survey from 1999 to 2016 and 
evaluated trends and disparities in the quality for diabetes care. 
The results showed an overall improvement in diabetes 
management during the study period as indicated by the 
proportion of respondents meeting HbA1c, BP, LDL-C and 
triglyceride goals. We observed that the prevalence of diabetes 
increased with lower education, as well as an upward trend in 
percentage of Hispanics with diabetes over the study period. 
These changes are likely attributable to inadequate insurance 
coverage, lack of health knowledge, and resultant suboptimal 
diabetes preventive care and management, all of which are 
particularly prevalent among Hispanic populations (3, 16, 17).  
 
Over the past decades, numerous efforts have been made 
nationwide to reduce disparities in diabetes care (2-4, 7) and 
national treatment guidelines revised toward race-specific 
treatment paradigms (11, 12, 15). Despite these efforts, 
substantial gaps in diabetes treatment and outcomes persist in 
US populations. Overall, whites were more likely to have 
achieved most diabetes care goals than minorities. Blacks 
exhibited normal triglyceride levels that is attributable to higher 
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lipase activity among them (17). There has been a significant 
increase in the use of statin over the past few decades which is 
associated with paralleled decrease in LDL-C and triglycerides 
levels observed in our study.  
 
Despite continuous innovation in glucose-lowering 
medications, the overall declining glycemic control may be due 
to changes in the characteristics of adults with type 2 diabetes 
and increase in patient cost sharing in U.S. healthcare plans 
(19). In general, significantly higher rates of uncontrolled BP, 
LDL-C and triglyceride levels were observed among Hispanics, 
adults with low SES, uninsured populations, individuals not 
taking statins or diabetes medications and adults with certain 
comorbid conditions such as hypertension and cardiovascular 
disease. Improvement in HbA1c, BP and lipid profile observed 
during the study period reflects availability of innovative 
diabetes medications. Yet a substantial proportion of adults 
with diabetes, particularly blacks and Hispanics were less likely 
to meet the recommended goals (20-22).  
 
Suboptimal insurance coverage and lower socioeconomic 
status are among the strongest predictors of poor quality of 
diabetes care. After adjusting for confounders, older adults, 
whites, individuals with higher educational status, and adults 
with insurance were more likely to meet the HbA1c goal. In our 
study, SES had a significant impact on meeting HbA1c, BP and 
LDL-C goals. Other studies have reported a decline in the 
proportion of patients with poor BP between 1988-2008; 
however, SES-related disparities remained (22, 23, 24). Lack of 
health insurance and presence of comorbidities were found to 
be associated with lower rates of eye and foot examination. The 
reasons for these persistent disparities are complex and further 
research is needed to understand the mechanism underlying 
these disparities.  
 
In our study, the likelihood of receiving eye checkups increased 
with age, this is likely attributable to the higher prevalence of 
diabetes retinopathy among older patients (24). Similarly, older 
adults were more likely to have their feet checked for sores. 
Given that the risk of lower extremity amputations increases 
with age and duration of diabetes, routine foot examination for 
sores or irritation effectively reduces such risks (25). The 
greater prevalence of diabetes and diabetic complications 
among older adults, is also indicative of the higher likelihood of 
meeting with a diabetes educator, particularly as the disease 
may become more advanced with older age. 
 
 
Strengths and Limitations 
A strength of this study was the use of a nationally 
representative sample allowing generalization to the US adult 
noninstitutionalized population. Health care utilization 
information and clinical outcomes were assessed using 
standardized procedures, which allows us to better 
characterize diabetes management.  The nature of NHANES 
data opens the study to several limitations. This is a serial cross-
sectional study with inherent limitations due to observational 
study design and residual confounding. Respondents were less 
likely to report their exact income thus resulting in potential 
misclassification. Insurance was dichotomized as ‘insured’ 
versus ‘uninsured’ and did not account for specific insurance 
types. Some important causal relationships such as lifestyle 
characteristics and quality of diabetes care cannot be examined 
although educational status and healthcare utilization are 
shown to be heavily correlated with lifestyles (29). Also the 
report of drug use only includes prescription medications that 
have been used in the past 30 days. Moreover, the recordings 
of BP represent one-day measurements as opposed to average 
measurement from several visits as recommended by 2017 
American College of Cardiology/American Heart Association 
Guidelines. 
 
Conclusion 
The findings from this study provide insight into the current 
status and trends of quality of diabetes care in the US. The study 
results highlight persistent sociodemographic disparities and 
areas for improvement in diabetes management. 
Implementations of various guidelines to advance quality of 
diabetes care are among the many efforts to improve 
treatment outcomes of diabetes. Despite these efforts and 
overall improvements, suboptimal outcomes in diabetes care 
were still observed among blacks and Hispanics, uninsured 
populations and other socioeconomically disadvantaged 
groups. Targeted prevention approaches and disease 
management paradigm are needed for high-risk populations to 
achieve improved quality and equity in diabetes care.    
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Table 1. Prevalence of Controlled Hemoglobin A1C (HbA1c< 8%) among Adults with Diabetes-NHANES, 1999-2016 
Variables 
Overall 
(n=7521) 
 
1999-2004 
(n=1960) 
 
2005-2010 
(n=2663) 
 
2011-2016  
(n=2898) 
P trend 
(adjusted) 
All patients  75.4 (0.8) 71.9 (1.4) 74.0 (1.2) 79.9 (1.4) <0.001 
Race and ethnicity 
     
Whites 79.5 (1.0) 76.3 (2.0) 82.0 (3.0) 85.7 (3.0) <0.01 
Blacks 71.3 (1.1) 65.3 (3.0) 70.7 (1.6) 75.5 (1.6) 0.03 
Hispanics 64.1 (1.6) 59.3 (3.4) 68.6 (3.0) 67.5 (2.4) 0.39 
Others 73.8 (2.8) 70.5 (1.8) 78.5 (1.3) 79.7 (1.8) 0.45 
Education 
     
Less than high school 72.6 (1.2) 66.8 (2.1) 70.6 (1.8) 71.2 (2.1) <0.001 
High school graduate 73.3 (1.4) 70.0 (2.2) 72.0 (2.2) 76.2 (2.5) 0.09 
Some college  77.6 (1.3) 72.5 (2.8) 79.0 (1.9) 78.0 (2.0) 0.12 
College graduate or above 84.7 (1.7) 83.9 (3.5) 84.1 (2.7) 86.0 (2.6) 0.21 
 
Poverty-to-income ratio (PIR) 
     
<100% 70.1 (1.4) 67.8 (3.3) 69.9 (2.4) 71.5 (2.0) 0.02 
100%-299% 74.0 (1.1) 72.0 (2.2) 70.1 (1.4) 78.2 (2.0) 0.12 
300%-499% 76.3 (1.8) 71.8 (3.8) 81.9 (2.3) 79.8 (2.0) 0.56 
≥500% 79.5 (1.9) 73.9 (3.2) 83.8 (2.8) 83.6 (3.5) 0.77 
Insurance 
     
Insured 78.3 (2.2) 75.4 (1.5) 76.7 (1.2) 82.5 (1.3) <0.001 
Uninsured 61.9 (0.8) 57.2 (3.1) 67.9 (2.9) 59.6 (3.6) 0.11 
Diabetes medication 
     
Oral medications only 80.0 (0.9) 72.6 (1.9) 80.9 (1.3) 84.0 (1.4) <0.001 
Insulin only 58.0 (2.2) 54.9 (3.4) 56.2 (4.2) 61.1 (3.5) 0.32 
Oral medications and insulin 51.6 (2.4) 49.6 (4.8) 46.3 (3.8) 59.8 (3.4) 0.21 
None 85.6 (1.1) 84.6 (1.9) 89.3 (1.6) 82.7 (2.0) 0.32 
 
Statin use 
     
Yes 79.2 (1.2) 74.1 (2.7) 80.2 (1.4) 86.7 (2.4) 0.01 
No 70.2 (1.1) 69.3 (1.6) 71.5 (1.8) 70.3 (2.3) 0.44 
Co-morbidities 
     
Hypertension 75.1 (1.6) 74.5 (1.5) 76.2 (1.1) 76.7 (1.5) 0.16 
Chronic kidney disease  72.4 (1.0) 69.2 (2.7) 76.2 (1.9) 69.6 (2.4) 0.52 
Cardiovascular disease  70.5 (1.5) 70.7 (1.3) 68.0 (1.4) 71.8 (1.5) 0.70 
Albuminuria 65.3 (1.4) 63.4 (2.5) 63.9 (2.0) 62.7 (2.4) 0.33 
Data are presented as percentages and Standard Error (SE) 
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Table 2. Prevalence of Controlled Blood Pressure (< 130/80 mm Hg) among Adults with Diabetes-NHANES, 1999-2016 
Variables 
Overall 
(n=7521) 
1999-2004 
(n=1960) 
2005-2010 
(n=2663) 
2011-2016 
(n=2898) 
P trend 
(adjusted) 
All patients  51.3 (0.8) 42.3 (1.8) 48.8 (1.3) 51.2 (1.4) <0.001 
Race and ethnicity      
Whites 51.4 (1.3) 44.5 (2.7) 51.8 (1.9) 53.8 (2.1) 0.01 
Blacks 44.4 (1.5) 43.8 (1.5) 49.6 (1.9) 53.3 (2.2) 0.03 
Hispanics 40.5 (1.2) 36.8 (2.6) 42.8 (1.7) 40.7 (2.1) 0.26 
Others 53.3 (1.6) 41.2 (2.9) 52.6 (2.0) 59.8 (2.3) <0.001 
Education      
Less than high school 44.2 (1.3) 37.1 (2.2) 44.4 (2.0) 47.8 (2.3) <0.001 
High school graduate 46.1 (1.5) 42.4 (3.0) 46.4 (2.2) 48.6 (2.7) 0.18 
Some college  50.2 (1.6) 44.5 (3.3) 53.4 (2.5) 50.8 (2.4) 0.42 
College graduate or above 55.4 (2.2) 50.6 (4.7) 60.4 (4.0) 54.2 (3.1) 0.28 
Poverty-to-income ratio (PIR)      
<100% 44.5 (1.6) 38.5 (2.8) 46.0 (3.2) 47.1 (2.4) 0.02 
100%-299% 46.5 (1.2) 40.0 (2.4) 48.9 (1.6) 50.1 (2.0) <0.001 
300%-499% 54.0 (2.0) 49.4 (5.1) 54.9 (3.9) 55.7 (3.8) 0.45 
≥500% 50.0 (2.6) 44.5 (1.9) 54.1 (1.9) 50.6 (2.0) 0.75 
Insurance      
Insured 54.3 (1.9) 47.0 (2.0) 54.0 (1.5) 57.4 (1.4) <0.001 
Uninsured 45.6 (0.9) 46.8 (4.6) 45.5 (2.8) 44.6 (3.0) 0.35 
Statin use      
Yes 57.9 (1.4) 42.9 (3.6) 56.2 (2.0) 61.9 (2.3) 0.03 
No 45.8 (1.2) 42.1 (2.1) 42.1 (1.7) 47.3 (2.4) 0.07 
Diabetes Medication      
Oral medications only 51.0 (1.2) 45.6 (2.1) 54.0 (2.1) 50.4 (2.0) 0.22 
Insulin 57.4 (2.5) 52.2 (4.5) 59.0 (3.8) 59.0 (4.4) 0.47 
Oral medication and insulin 54.4 (2.3) 47.8 (5.3) 51.6 (3.1) 58.8 (3.3) <0.01 
None 47.8 (2.0) 47.2 (1.4) 44.3 (3.7) 49.5 (2.9) 0.18 
Co-morbidities      
Hypertension 31.5 (0.9) 22.8 (1.8) 34.2 (1.2) 34.4 (1.6) <0.01 
Chronic Kidney Disease 37.9 (1.4) 30.9 (3.5) 41.7 (2.1) 38.7 (2.0) 0.29 
Cardiovascular disease 49.4 (1.1) 38.2 (2.9) 45.9 (2.1) 50.4 (2.7) 0.05 
Albuminuria 31.3 (1.4) 28.3 (2.8) 37.2 (2.1) 28.3 (2.2) 0.08 
Data are presented as percentages and Standard Error (SE) 
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Table 3. Prevalence of Controlled LDL-C (<100 mg/dL) among Adults with Diabetes -NHANES, 1999-2014 
Variables 
Overall 
(n=2750) 
 
1999-2002 
(n=454) 
 
2003-2006 
(n=543) 
 
2007-2010 
(n=910) 
2011-2014 
(n=843) 
 
Ptrend 
(adjusted) 
All patients  46.6 (1.3) 31.9 (3.4) 44.2 (2.7) 50.5 (2.4) 52.5 (2.2) <0.001 
Race and ethnicity 
      
Whites 49.7 (1.4) 34.6(5.0) 45.4 (3.6) 55.5 (3.3) 56.9 (3.3) <0.001 
Blacks 40.5 (5.0) 27.9(0.8) 39.7 (1.7) 40.6 (1.4) 45.5 (1.6) 0.02 
Hispanics 36.6 (4.0) 24.7(2.2) 37.6 (2.1) 41.4 (3.6) 33.9 (4.6) 0.48 
Others 47.5 (2.4) 33.8(3.2) 40.5 (3.9) 51.3 (2.8) 52.6 (3.7) 0.12 
Education 
      
Less than high school 45.2 (0.8) 29.5 (1.2) 42.8 (1.6) 48.6 (1.6) 49.4 (1.4) <0.01 
High school graduate 46.5 (1.0) 34.8 (3.0) 41.7 (1.7) 57.8 (2.5) 46.1 (1.9) 0.24 
Some college 47.6 (1.1) 24.9 (1.5) 46.7 (1.7) 47.9 (1.7) 57.3 (2.1) 0.03 
College graduate or above 55.6 (0.8) 48.0 (1.7) 47.8 (1.8) 50.9 (3.0) 52.4 (2.3) 0.19 
Poverty-to-income ratio (PIR) 
      
<100% 37.4 (0.6) 20.4 (1.3) 32.7 (1.2) 41.6 (1.4) 45.6 (2.2) <0.01 
100%-299% 46.3 (1.3) 31.3 (1.2) 39.3 (1.3) 48.6 (1.7) 50.7 (1.7) 0.03 
300%-499% 50.7 (1.0) 40.2 (2.6) 47.5 (1.9) 55.9 (2.0) 59.6 (3.0) 0.01 
≥500% 48.9 (1.0) 47.5 (2.5) 44.9 (2.4) 49.6 (3.2) 53.7 (2.7) 0.29 
Insurance 
      
Insured 48.3 (0.5) 41.7 (0.8) 47.3 (0.9) 53.5 (1.2) 54.0 (1.2) 0.02 
Uninsured 35.1 (1.3) 29.1 (1.1) 32.3 (1.7) 35.7 (1.9) 33.6 (1.9) 0.95 
Statin use 
      
Yes 68.6 (1.0) 45.7 (2.9) 65.9 (1.5) 71.3 (2.0) 72.1 (2.2) <0.01 
No 30.9 (1.2) 28.0 (0.9) 33.0 (0.8) 30.2 (0.9) 32.4 (1.7) 0.34 
Diabetes Medication 
      
Oral medications only 52.5 (1.5) 34.8 (0.8) 50.0 (1.2) 53.8 (1.6) 59.6 (1.5) <0.001 
Insulin 55.3 (0.7) 24.3 (2.6) 64.9 (2.5) 59.0 (3.9) 51.1 (4.1) 0.10 
Oral medication and insulin 51.7 (0.7) 37.2 (1.3) 53.6 (2.8) 60.8 (3.3) 60.4 (4.6) 0.24 
None 39.2 (0.9) 27.9 (2.6) 38.1 (1.2) 42.1 (2.1) 40.1 (1.9) 0.48 
Co-morbidities 
      
Hypertension 51.7 (0.8) 33.4 (0.9) 50.7 (0.9) 56.1 (1.4) 56.4 (1.5) 0.47 
Chronic Kidney Disease 53.6 (1.3) 38.0 (1.2) 51.9 (1.9) 60.6 (2.3) 61.9 (2.1) 0.16 
Cardiovascular disease 58.4 (0.8) 41.2 (1.1) 49.1 (2.4) 65.2 (1.6) 63.7 (2.7) 0.24 
Albuminuria 48.8 (1.3) 33.7 (0.8) 48.5 (0.9) 48.9 (1.3) 59.1 (1.1) 0.14 
Data are presented as percentages and Standard Error (SE) 
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Table 4. Prevalence of Controlled Triglycerides (<150 mg/dL) among Adults with Diabetes-NHANES 1999-2014 
Variables 
Overall 
(n=2750) 
 
1999-2002 
(n=454) 
 
2003-2006 
(n=543) 
 
2007-2010 
(n=910) 
 
2011-2014 
(n=843) 
 
Ptrend 
(adjusted) 
All patients  53.0 (1.5) 45.4 (2.9) 47.6 (2.9) 55.8 (2.1) 58.8 (3.5) <0.001 
Race and ethnicity 
      
Whites 50.8 (1.6) 43.0 (1.1) 47.5 (1.4) 54.6 (1.5) 56.9 (2.3) 0.02 
Blacks 72.4 (0.8) 62.4 (1.5) 68.6 (1.9) 72.9 (2.2) 79.9 (2.5) <0.01 
Hispanics 47.8 (0.8) 49.6 (3.0) 42.7 (2.2) 45.9 (1.9) 51.5 (1.9) 0.53 
Others 47.5 (0.5) 41.9 (3.2) 45.5 (1.1) 56.0 (4.0) 54.8 (3.4) 0.15 
Education 
      
Less than high school 50.2 (0.8) 44.4 (3.6) 47.2 (3.4) 48.1 (3.7) 58.7 (4.1) 0.03 
High school graduate 51.8 (0.9) 45.5 (5.7) 47.0 (4.5) 57.5 (3.0) 57.8 (4.4) 0.02 
Some college 53.0 (1.0) 38.9 (1.1) 49.2 (1.8) 55.7 (1.6) 59.0 (2.8) <0.01 
College graduate or above 59.0 (0.9) 58.6 (1.9) 50.8 (2.2) 65.4 (3.0) 59.6 (3.1) 0.64 
Poverty-to-income ratio (PIR) 
      
<100% 47.8 (0.7) 32.0 (1.3) 40.1 (1.6) 49.0 (1.2) 51.0 (2.5) 0.01 
100%-299% 54.5 (1.3) 50.9 (1.5) 49.5 (1.8) 54.7 (1.4) 60.9 (2.0) 0.14 
300%-499% 51.0 (1.0) 41.2 (1.6) 45.0 (2.1) 58.5 (2.0) 51.3 (2.7) 0.12 
≥500% 57.0 (1.1) 52.8 (1.9) 60.4 (2.2) 66.9 (3.6) 68.4 (4.3) 0.02 
Insurance 
      
Insured 58.2 (0.5) 47.0 (0.9) 49.3 (1.1) 56.9 (1.1) 60.8 (1.6) 0.02 
Uninsured 45.0 (1.6) 42.5 (2.2) 36.7 (1.7) 50.5 (1.8) 49.2 (1.8) 0.54 
Statin use 
      
Yes 56.1 (1.1) 49.5 (3.0) 54.5 (1.2) 57.1 (1.3) 64.2 (1.2) 0.02 
No 51.2 (1.0) 43.8 (1.1) 46.8 (1.0) 52.6 (1.1) 51.4 (1.3) 0.13 
Diabetes Medication 
      
Oral medications only 52.3 (1.5) 40.9 (0.9) 46.5 (1.3) 53.5 (1.3) 61.6 (2.1) 0.03 
Insulin 67.1 (0.7) 69.5 (1.8) 56.2 (2.7) 61.3 (3.9) 68.0 (4.2) 0.55 
Oral medication and insulin 51.5 (0.6) 37.8 (1.2) 43.5 (2.9) 52.3 (3.4) 51.9 (3.4) 0.50 
None 54.9 (1.0) 50.9 (2.5) 49.4 (2.1) 59.8 (2.4) 55.9 (2.4) 0.44 
Co-morbidities 
      
Hypertension 53.4 (1.3) 45.4 (1.0) 48.2 (1.1) 54.9 (1.1) 59.5 (1.6) 0.03 
Chronic Kidney Disease 56.3 (1.4) 46.4 (1.6) 56.3 (1.9) 61.3 (1.5) 64.7 (2.2) <0.001 
Cardiovascular disease 52.2 (0.9) 40.1 (1.5) 49.1 (1.7) 55.8 (1.5) 55.9 (1.9) 0.02 
Albuminuria 46.9 (1.4) 36.9 (1.0) 43.7 (1.1) 52.6 (1.2) 50.4 (1.5) 0.10 
Data are presented as percentages and Standard Error (SE) 
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Tables 5: Adjusted Odds Ratios for Achieving Quality Indicators for Diabetes Care among Adults with Diabetes, NHANES 1999-2016 
Variables HbA1c <8%  
BP <130/80 
mm/Hg 
LDL-C <100 
mg/dL             
Triglycerides 
<150 mg/dL)              
Receipt of eye 
examination   
Receipt of foot 
examination   
Visited a diabetes 
educator           
Age (ref: 20 to 39)               
40 to 59 1.08 (0.76-1.54) 0.97 (0.71-1.32) 0.70 (0.42-1.19) 0.61 (0.39-1.26) 1.62 (0.99-1.98) 1.33 (0.91-1.94) 1.05 (0.90-1.26) 
≥60 1.75 (1.16-2.63)* 0.64 (0.46-0.89)* 1.27 (1.01-1.58)* 0.76 (0.56-0.99)* 2.51 (1.48-4.26)* 1.63 (1.03-2.58)* 1.28 (1.43-1.31)* 
Gender                
Women vs. men 0.57 (0.50-0.66)* 1.09 (0.92-1.29) 0.66 (0.51-0.84)* 0.91 (0.71-1.16) 1.22 (0.97-1.54) 1.14 (0.86-1.51) 1.12 (0.91-1.30) 
Educational status                      
(ref: < high school) 
    
  
  
  
    
High school  
graduate 
1.01 (0.77-1.23) 1.01 (0.81-1.25) 1.01 (0.67-1.11) 1.11 (0.85-1.45) 1.01 (0.81-1.25) 1.26 (0.95-1.67) 1.08 (0.83-1.39) 
Some college  1.03 (0.78-1.26) 1.15 (0.93-1.43) 1.40 (0.62-1.42) 1.23 (0.93-1.61) 1.15 (0.93-1.43) 1.29 (0.93-1.77) 1.18 (0.90-1.53) 
College  
graduate or  
above 
1.42 (1.03-1.96)* 1.25 (0.94-1.68) 1.43 (1.14-2.39)* 1.58 (1.05-2.39)* 1.25 (1.10-1.68) 1.85 (1.15-2.97)* 1.38 (1.10-1.65)* 
Poverty income-ratio 
(ref: <100%) 
    
  
  
  
    
100%-299% 1.07 (0.84-1.37) 0.94 (0.77-1.14) 1.29 (0.90-1.86) 1.31 (0.96-1.78) 1.28 (0.98-1.59) 0.94 (0.71-1.25) 1.05 (0.81-1.35) 
300%-499% 1.30 (0.62-1.24) 1.03 (0.77-1.31) 1.30 (1.00-2.10)* 1.00 (0.68-1.45) 1.33 (1.11-2.11)* 0.97 (0.67-1.41) 1.09 (0.85-1.40) 
≥500% 1.60 (0.64-1.34) 1.13 (0.58-1.08) 1.41 (0.80-2.50) 1.32 (0.86-2.12) 1.40 (0.84-1.97) 1.40 (0.90-2.18) 1.33 (1.06-1.54) 
Race and ethnicity         
(ref: whites) 
    
  
  
  
    
Blacks 0.77 (0.63-0.96)* 0.75 (0.63-0.89)* 0.68 (0.51-0.90)* 3.61 (2.63-4.95)* 1.37 (1.06-1.78)* 1.42 (1.07-1.88) 1.40 (1.12-1.75)* 
Hispanics 0.62 (0.49-0.79)* 0.52 (0.35-0.72)* 0.64 (0.44-0.92)* 1.21 (0.88-1.68) 1.05 (0.80-1.38) 0.83 (0.62-0.95)* 1.15 (0.91-1.50) 
Others 0.88 (0.58-1.33) 1.02 (0.77-1.49) 1.23 (0.79-1.94) 0.78 (0.48-1.28) 1.19 (0.82-1.72) 0.97 (0.62-1.51) 0.92 (0.58-1.45) 
*Estimates are statistically significant at P < 0.05. 
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Tables 5: Adjusted Odds Ratios for Achieving Quality Indicators for Diabetes Care among Adults with Diabetes, NHANES 1999-2016 (continued) 
Insurance                
Uninsured vs. 
insured 
0.56 (0.44-0.72)* 0.81 (0.62-0.99)* 0.78 (0.58-0.82)* 0.74 (0.53-0.85)* 0.81 (0.62-0.92)* 0.53 (0.38-0.74)* 1.04 (0.73-1.55) 
BMI, kg/m2 (ref:<25)                       
25-<30 1.06 (0.76-1.46) 1.22 (0.95-1.57) 0.83 (0.56-1.31) 0.56 (0.39-0.80)* 0.78 (0.56-1.09) 0.75 (0.51-1.11) 0.94 (0.75-1.25) 
≥30 0.84 (0.61-1.17) 1.29 (0.96-1.53) 0.89 (0.59-1.35) 0.50 (0.36-0.71)* 0.90 (0.65-1.24) 0.82 (0.54-1.25) 1.12 (1.01-1.34)* 
Current smoker               
Yes vs. no 0.88 (0.68-1.14) 0.82 (0.73-1.11) 1.07 (0.78-1.47) 0.85 (0.62-1.17) 0.62 (0.48-0.79)* 1.29 (0.90-1.86) 0.76 (0.54-1.07) 
Statin use                
Yes vs. no 1.19 (0.97-1.47) 1.28 (1.07-1.54)* 3.84 (2.89-5.09)* 1.15 (0.89-1.48) 1.54 (1.20-1.97)* 1.36 (1.03-1.80)* 0.86 (0.67-0.95)* 
Diabetes education      
(ref: none) 
    
  
  
  
    
Oral   
medications  
only 
2.40 (1.96-2.47)* 1.52 (1.27-1.82)* 1.64 (1.26-2.17)* 0.97 (0.76-1.24) 0.86 (0.56-1.03) 1.32 (0.98-1.45) 2.70 (1.89-3.84) 
Insulin only 1.60 (1.40-1.80)* 0.95 (0.77-1.09) 0.97 (0.80-1.03) 0.92 (0.84-1.09) 1.79 (1.38-2.59)* 2.72 (1.86-4.02)* 1.37 (0.95-1.66) 
Oral  
medications  
and insulin 
1.32 (0.93-1.37) 1.03 (0.89-1.33) 1.13 (0.96-1.26) 1.02 (0.91-1.18) 1.00 (0.92-1.24) 1.20 (0.84-1.03) 1.40 (1.27-1.68) 
Comorbidities (ref: 
without comorbidity) 
    
  
  
  
    
Hypertension 0.57 (0.33-0.76)* 0.23 (0.19-0.28)* 0.89 (0.66-1.35) 0.93 (0.72-1.19) 0.97 (0.78-1.31) 1.15 (0.91-1.46) 0.98 (0.76-1.26) 
Chronic kidney  
disease 
0.89 (0.70-1.15) 0.95 (0.77-1.16) 1.01 (0.71-1.39) 1.19 (0.88-1.60) 1.04 (0.82-1.29) 1.41 (1.01-1.97) 1.30 (0.99-1.73) 
Cardiovascular     
disease 
1.02 (0.79-1.31) 1.18 (0.96-1.45) 1.00 (0.72-1.40) 0.87 (0.66-1.15) 1.47 (1.12-1.94)* 0.99 (0.68-1.23) 1.20 (0.90-1.49) 
Albuminuria 0.48 (0.39-0.60)* 0.49 (0.41-0.59)* 1.11 (0.82-1.49) 0.62 (0.46-0.82)* 1.00 (0.73-1.35) 0.92 (0.69-1.23) 1.19 (0.95-1.49) 
*Estimates are statistically significant at P < 0.05. 
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Supplemental Table 1. Sociodemographic and Clinical Characteristics of Adults with Diabetes (≥20 Years Old) -NHANES, 1999-2016 
Variables 
Overall                  
SE 
1999-2004 
SE 
2005-2010            
SE 
2011-2016            
SE Ptrend % (95% CI) % (95% CI) % (95% CI) % (95% CI) 
n=7521 n=1960 n=2663 n=2898 
Age (years)                   
20-39 9.3 (8.5-10.1) 0.4 9.9 (7.6-12.1) 1.1 9.3 (8.1-10.4) 0.6 7.8 (6.8-10.1) 0.6 0.03 
40-59 39.4 (37.8-41.0) 0.8 40.7 (38.0-43.4) 1.4 39.4 (36.7-42.1) 1.4 39.7 (35.8-41.3) 1.4 0.06 
≥60 51.2 (49.5-52.9) 0.9 49.3 (45.9-52.7) 1.7 51.2 (48.3-54.1) 1.5 52.4 (49.7-55.0) 1.3 <0.01 
Female 48.8 (47.2-50.3) 0.8 49.0 (46.7-51.2) 1.1 49.5 (46.7-52.3) 1.4 48.1 (45.5-50.7) 1.3 0.57 
Educational Status                   
< High school 27.7 (26.1-29.2) 0.8 34.2 (27.4-36.9) 1.4 27.3 (22.1-30.4) 1.1 23.0 (20.9-25.4) 1.4 <0.001 
High school graduate 24.7 (23.1-26.3) 0.8 25.3 (22.4-28.1) 1.4 26.2 (23.0-29.3) 1.6 23.3 (20.9-25.4) 1.2 0.19 
Some college  29.2 (27.5-30.8) 0.8 25.8 (22.9-28.6) 1.5 28.8 (25.0-30.7) 1.4 32.4 (29.8-34.9) 1.3 <0.001 
College education or above 18.3 (16.7-19.9) 0.8 14.6 (12.3-17.0) 1.2 17.7 (15.1-20.0) 1.2 21.3 (18.1-24.2) 1.5 <0.001 
Poverty-to-income ratio                    
<100% 17.2 (15.8-18.7) 0.8 17.3 (14.7-19.9) 1.3 14.6 (12.2-16.6) 1.1 19.6 (16.9-22.2) 1.4 0.08 
100-299% 42.9 (41.1-44.6) 0.9 44.9 (41.2-48.5) 1.8 44.5 (42.1-47.6) 1.4 39.9 (37.1-42.8) 1.4 0.04 
300-499% 22.2 (15.8-18.7) 0.8 22.0 (19.3-24.6) 1.3 21.2 (18.6-23.5) 1.2 23.3 (20.3-26.1) 1.5 0.33 
≥500% 17.6 (15.9-19.3) 0.9 15.7 (12.6-18.8) 1.6 19.6 (17.3-21.9) 1.2 17.1 (14.0-20.3) 1.6 0.57 
Race and ethnicity                   
Whites 61.0 (57.9-64.1) 1.6 63.8 (58.4-68.9) 2.7 62.5 (57.0-67.8) 2.7 58.2 (53.0-63.4) 2.6 0.01 
Blacks 15.9 (14.0-17.5) 1.0 15.3 (12.0-18.5) 1.7 16.8 (13.8-17.6) 1.5 15.6 (12.2-18.8) 1.7 0.98 
Hispanics 15.1 (12.7-17.5) 1.2 13.9 (9.1-18.9) 2.5 14.0 (10.4-17.6) 1.8 16.6 (12.6-20.5) 2.0 <0.001 
Others 7.9 (6.7-9.0) 0.6 6.9 (4.6-9.1) 1.2 6.6 (4.9-8.3) 0.9 9.5 (7.6-11.5) 1.0 0.06 
Insured  87.8 (86.8-88.8) 0.5 87.9 (86.1-89.8) 0.9 87.3 (85.3-89.2) 1.0 88.2 (86.8-89.6) 0.7 0.73 
BMI, kg/m2                   
<25 12.7 (11.5-13.9) 0.6 15.0 (12.0-18.1) 1.5 12.8 (11.2-14.4) 0.8 11.7 (9.5-13.0) 0.9 0.02 
25-<30 26.7 (25.3-28.1) 0.7 30.1 (27.0-33.2) 1.6 25.6 (23.2-28.1) 1.2 26.1 (23.5-27.8) 1.1 0.14 
≥30 60.5 (58.6-62.4) 1.0 54.8 (50.6-58.8) 2.1 61.5 (58.5-64.4) 1.5 62.1 (59.9-66.0) 1.5 <0.01 
Current smoker 17.1 (16.0-18.1) 0.5 19.7 (17.6-21.8) 1.1 17.0 (15.3-18.7) 0.9 15.5 (13.9-17.2) 0.9 <0.01 
Statin user 57.6 (55.9-59.4) 0.9 28.4 (25.3-31.5) 1.0 46.3 (44.1-48.5) 1.1 50.1 (46.6-53.7) 1.8 <0.001 
Diabetes medication                   
Oral medications 55.0 (53.2-56.9) 0.8 55.8 (52.3-59.2) 1.2 56.8 (51.4-58.4) 1.5 57.9 (52.1-60.1) 1.3 0.001 
Insulin 13.2 (11.7-14.1) 0.5 15.8 (12.8-18.9) 1.3 12.9 (10.9-14.8) 0.8 11.5 (9.8-13.1) 0.8 0.01 
Oral medications and insulin 12.5 (11.4-13.6) 0.5 10.4 (7.6-13.0) 1.1 10.7 (11.9-15.4) 0.7 10.5 (11.1-14.1) 0.8 0.21 
HbA1c<8% 75.3 (74.1-77.0) 0.8 72.1 (70.2-75.4) 1.3 73.6 (72.0-77.3) 1.3 79.6 (77.8-81.4) 1.3 <0.001 
Blood pressure control                   
<140/90 mm Hg 71.5 (69.9-73.0) 0.8 67.4 (64.7-70.1) 1.4 71.8 (69.5-74.1) 1.2 73.6 (70.9-76.4) 1.4 0.01 
<130/80 mm Hg 48.6 (46.8-50.3) 0.8 42.3 (38.6-46.1) 1.8 50.2 (47.5-53.0) 1.3 51.1 (48.4-53.7) 1.4 0.03 
Lipid profile                   
LDL-C ≤100 mg/dL  46.6 (44.0-49.2) 1.3 35.0 (30.1-40.0) 2.5 50.6 (46.7-54.6) 2.0 51.4 (47.0-55.8) 2.2 <0.001 
Triglycerides ≤ 150mg/dL 53.2 (50.3-56.2) 1.5 44.3 (39.9-48.6) 2.2 54.5 (50.5-58.5) 2.0 58.4 (51.4-65.5) 2.5 <0.001 
Health services use in the past year                    
Foot exam 71.5 (69.4-73.7) 1.1 * * 71.4 (68.7-74.0) 1.3 71.8 (68.5-75.0) 1.6 0.35 
Eye exam  63.8 (61.1-65.8) 1.2 * * 63.7 (60.5-66.9) 1.6 63.0 (59.6-66.5) 1.7 0.76 
Visited diabetes educator 36.9 (34.9-39.0) 1.0 * * 38.5 (35.3-41.7) 1.6 34.8 (32.4-37.1) 1.2 0.06 
Comorbidities                   
Hypertension 64.8 (63.1-66.5) 0.8 61.3 (58.3-64.4) 1.5 65.8 (62.9-68.6) 1.5 65.9 (63.2-68.7) 1.4 <0.001 
Chronic kidney disease 22.4 (21.3-23.5) 0.6 21.6 (19.5-23.7) 1.1 22.3 (20.3-24.3) 1.0 22.9 (21.2-24.6) 0.9 0.01 
Cardiovascular diseases 23.3 (21.9-24.7) 0.7 23.7 (20.4-27.1) 1.7 23.9 (21.7-26.1) 1.1 22.6 (20.7-24.4) 0.9 0.47 
Albuminuria 27.3 (25.9-28.7) 0.7 30.9 (28.8-33.1) 1.1 27.0 (25.0-29.1) 1.0 25.4 (22.7-28.0) 1.3 <0.01 
HbA1c = glycated haemoglobin; LDL-C = Low Density Lipoprotein Cholesterol; CI = confidence interval; SE = standard error.  
*Data not available at the time of the study.  
